Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped RXRX stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Recursion Pharmaceuticals, Inc. (RXRX) is positioned as a growth-oriented pharmaceutical stock leveraging AI-driven technologies and robust pipelines. The recent developments in drug trials and key partnerships signal substantial upside. While regulatory challenges and profitability concerns provide bearish scenarios, the overall sentiment remains bullish based on extraordinary revenue growth projections, analysts' upgrades, and strategic measures poised to expand market dominance. The saved 1-year distribution is P10 $2.65, P50 $5, and P90 $9.
Last analyzed · Model: gpt-4o
Recursion Pharmaceuticals, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.65 | Pessimistic plausible scenario |
| P50 | $5 | Median scenario |
| P90 | $9 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Recursion Pharmaceuticals benefits from a strong revenue growth projection, positive pipeline developments, and favorable analyst sentiment. Despite some recent regulatory setbacks, the overall sentiment leans bullish due to advancements in drug development and partnerships in AI.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this RXRX analysis generated?
April 1, 2026.
Is this a guaranteed RXRX prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full RXRX stock analysis · RXRX sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.